(3) Ethyl 2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetate. 1 H NMR (DMSO-d6, 400 MHz): (8.21, d, 1H, J= 8 Hz), (7.96, t, 1H, J= 8 Hz), (7.90, 2H), (4.14, t, 2H, J= 8 Hz), (4.10, s, 3H), (1.19, t, 3H, J= 10 Hz). (4) Ethyl 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetate. 1 H NMR (DMSO-d6, 400 MHz): (8.12, d, 1H, J= 8 Hz), (7.80, t, 1H, J= 7 Hz), (7.71, 2H), (3.96, q, 2H, J= 6-8 Hz), (3.90, s, 2H), (3.19, s, 1H), (1.02, t, 3H, J= 8 Hz). General procedure for the synthesis <strong>of</strong> 4-oxopthalazinyl-1-acetic acids. A solution <strong>of</strong> ester 3 or 4 (9.0 g, 37 mmol) <strong>and</strong> 10 eq. 3M NaOH (122 mL) in THF was refluxed for 3 hr under nitrogen atmosphere. The reaction mixture was acidified with 1.2 eq <strong>of</strong> 10 M HCl (47 mL), diluted with water, <strong>and</strong> extracted with CHCl3, which was dried with anhydrous MgSO4. Evaporation <strong>of</strong> CHCl3 yielded 7.9 g (5) or 7.8 g (6) (99%) <strong>of</strong> the desired product. (5) 2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid. 1 H NMR (DMSOd6, 400 MHz): (9.20, d, 1H, J= 8 Hz), (7.94, t, 1H, J= 8 Hz), (7.88, 2H), (3.99, s, 2H), (3.71, s, 3H). (6) 2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid. 1 H NMR (DMSO-d6, 400 MHz): (8.14, d, 1H, J= 8 Hz), (7.83, t, 1H, J= 8 Hz), (7.74, m, 2H, J= 8 Hz), (3.94, s, 2H), (2.39, s, 1H). 22
General procedure for the synthesis <strong>of</strong> 4-oxopthalazinyl-1-N-arylacetamides. 1.2 eq <strong>of</strong> triethylamine (TEA) (56mg, 0.55 mmol) was added to a solution <strong>of</strong> acid (4) or (5) (100mg, 0.46 mmol), 1.2 eq 1-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (EDCI-HCl) (105mg, 0.55 mmol), 1.2 eq hydroxybenzotriazole (HOBt) (74mg, 0.55 mmol) <strong>and</strong> 1.2 eq <strong>of</strong> aniline in 3mL DMSO under nitrogen atmosphere for 3 h. The reaction mixture was washed with 1.2 mL HCl <strong>and</strong> water, extracted with CHCl3, then washed again with NaHCO3, <strong>and</strong> dried with anhydrous MgSO4. Evaporation <strong>of</strong> CHCl3 <strong>and</strong> purification <strong>of</strong> the residues by column chromatography yielded the desired products in yields ranging from 5-95%. (7) N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.22, 1H, s), (8.30, d, 1H, J= 8 Hz), (7.95, m, 2H, J= 8 Hz), (7.86, t, 1H, J= 7 Hz), (7.48, d, 2H, J= 8 Hz), (6.88, d, 2H, J= 8 Hz), (4.06, s, 2H), (3.72, s, 3H), (3.71, s, 3H). (8) N-(3-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.27, s, 1H), (8.30, d, 1H, J= 8 Hz), (7.95, m, 2H, J= 7-8 Hz), (7.87, t, 1H, J= 8 Hz), (7.30, s, 1H), (7.21, t, 1H, J= 8 Hz), (7.11, d, 1H, J= 8 Hz), (6.64, d, 1H, J= 8 Hz), (4.09, s, 2H), (2.73, s, 3H), (2.70, s, 3H). (9) N-(2-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.27, s, 1H), (8.31, d, 1H, J= 8 Hz), (7.94, m, 23
- Page 1 and 2: Synthesis and Biological Evaluation
- Page 3 and 4: inducing enzyme inhibition. Further
- Page 5 and 6: List of Tables Table I. Table II. I
- Page 7 and 8: Introduction Outbreaks worldwide ha
- Page 9 and 10: Compound 7 and its analogs were pre
- Page 11 and 12: D21 9 Me 2-OMePh >5000 ND D23 10 Me
- Page 13 and 14: D35 51 Me thiazolyl) 2-(5-Me(1,3,4-
- Page 15 and 16: Figure III. Intramolecular interact
- Page 17 and 18: Figure IV. Ball-and-stick model of
- Page 19 and 20: methoxy group. We believe that this
- Page 21 and 22: enzofuran series of inhibitors. How
- Page 23 and 24: Trends in potency seemed to increas
- Page 25 and 26: Conclusion We have hypothesized, ap
- Page 27: chemical shift values are also repo
- Page 31 and 32: (15) N-(4-bromophenyl)-2-(3-methyl-
- Page 33 and 34: 1H, J= 7 Hz), (8.17, d, 1H, J= 9 Hz
- Page 35 and 36: (7.95, q, 2H, J= 7-8 Hz), (7.87, t,
- Page 37 and 38: 1H, J= 8 Hz), (7.31, d, 1H, J= 8 Hz
- Page 39: Bibliography 1. Huang, D.R.; White,